Tearsheet

Ascendis Pharma (ASND)

Market Price (9/4/2025): $200.1 | Market Cap: $12.1 Bil
Sector: Health Care | Industry: Biotechnology

Ascendis Pharma (ASND)

Market Price (9/4/2025): $200.1
Market Cap: $12.1 Bil
Sector: Health Care
Industry: Biotechnology

Market Valuation

	9/4/25	2024	2023	2022	2021
Share Price CYE	$200.10	$137.67	$125.95	$122.13	$134.53
Market Cap CYE ($ Bil)	12.1	8.2	7.1	6.8	7.6
Total Debt ($ Bil)	0.0	0.9	0.6	0.5	0.1
Total Cash ($ Bil)	0.0	0.6	0.4	0.7	0.7
Enterprise Value ($ Bil)	0.0	9.1	7.7	7.3	7.7
Valuation Ratios
P/S TTM	28.4	21.9	26.6	133.8	947.3
P/EBIT TTM	-58.5	-25.9	-16.5	-12.5	-19.4
P/E TTM	-42.3	-21.1	-14.7	-11.7	-19.2
Sector Ratios
P/S TTM (Sector)	3.8	4.1	4.5	4.5	6.7
P/EBIT TTM (Sector)	4.3	0.4	-1.9	-1.2	-0.4
P/E TTM (Sector)	-1.8	-2.2	-3.4	-2.2	-2.3

	9/4/25	2024	2023
Share Price CYE	$200.10	$137.67	$125.95
Market Cap CYE ($ Bil)	12.1	8.2	7.1
Total Debt ($ Bil)	0.0	0.9	0.6
Total Cash ($ Bil)	0.0	0.6	0.4
Enterprise Value ($ Bil)	0.0	9.1	7.7
Valuation Ratios
P/S TTM	28.4	21.9	26.6
P/EBIT TTM	-58.5	-25.9	-16.5
P/E TTM	-42.3	-21.1	-14.7
Sector Ratios
P/S TTM (Sector)	3.8	4.1	4.5
P/EBIT TTM (Sector)	4.3	0.4	-1.9
P/E TTM (Sector)	-1.8	-2.2	-3.4

Stock Price
Market Cap

Stock Price Chart

Return (1Y):

Market Cap Chart

Business Description

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. Show more

Price Returns Compared

Expand for Detailed View

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
ASND Return	20%	-19%	-9%	3%	9%	45%	-8%
Peers Return	11%	18%	23%	15%	2%	8%	103%
S&P 500 Return	16%	27%	-19%	24%	23%	10%	100%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, ABBV, AMGN, GILD, REGN.
[3] 2025 data is for the year up to 9/3/2025 (YTD)

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	XELA	Exela Technologies	212.4%	-95.5%
2	TKCM	Token Communities	82.8%	-64.7%
3	ANGGF	Angang Steel	61.2%	25.0%
4	BATMF	British American Tobacco Malaysia	43.4%	59.2%
5	KYSEF	Kyushu Electric Power	32.1%	32.1%
6	STTK	Shattuck Labs	26.7%	5.8%
7	KTHAF	Krung Thai Bank	24.0%	24.0%
8	SFOSF	Shanghai Fosun Pharmaceutical	23.7%	61.7%
9	INDOY	Indorama Ventures	20.9%	-5.5%
10	M	Macy's	20.7%	-1.0%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
2	MGAWF	Megaworld	-71.0%	-71.0%
3	PTTMF	PT Timah	-62.8%	-83.1%
4	PTJSF	PT Jasa Marga	-50.9%	-50.9%
5	UNLRF	PT Unilever Indonesia	-41.3%	-17.6%
6	DLNDY	D&L Industries	-37.5%	-30.7%
7	SUCEF	Sumitomo Osaka Cement	-37.4%	-37.4%
8	PTKFF	PT Kalbe Farma	-34.7%	-32.1%
9	SMTGF	SMA Solar Technology	-30.1%	28.4%
10	PMDKF	PT Mitra Adiperkasa	-28.6%	-48.9%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	EAF	GrafTech International	804.0%	-47.2%
2	RLMD	Relmada Therapeutics	122.3%	182.7%
3	XELA	Exela Technologies	109.6%	-95.5%
4	PSNYW	Polestar Automotive UK	96.2%	141.5%
5	TKCM	Token Communities	82.8%	-64.7%
6	PHJMF	PT Hanjaya Mandala Sampoerna	66.7%	34.8%
7	ANGGF	Angang Steel	61.2%	25.0%
8	DTNOF	DNO	49.5%	141.9%
9	BW	Babcock & Wilcox Enterprises	48.5%	54.9%
10	MDB	MongoDB	46.0%	34.4%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	NXTT	Next Technology	-74.5%	-89.4%
4	SCGY	Scientific Energy	-72.7%	-26.9%
5	MGAWF	Megaworld	-71.0%	-71.0%
6	TTOO	T2 Biosystems	-67.7%	-99.0%
7	PTTMF	PT Timah	-62.8%	-83.1%
8	PIGEF	Pigeon	-62.4%	-62.4%
9	NEGG	Newegg Commerce	-53.8%	290.6%
10	PTJSF	PT Jasa Marga	-50.9%	-50.9%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	MMEX	MMEX Resources	∞%	-50.0%
2	TAWNF	Thai Airways International	3674.5%	3400.0%
3	NOKPF	Nok Airlines	2400.0%	81.8%
4	AYRWF	Ayr Wellness	509.5%	-94.6%
5	XELA	Exela Technologies	379.0%	-95.5%
6	SRNE	Sorrento Therapeutics	233.3%	900.0%
7	PGEN	Precigen	169.9%	324.1%
8	TLS	Telos	154.7%	89.2%
9	SATS	EchoStar	142.7%	179.1%
10	RLMD	Relmada Therapeutics	139.0%	182.7%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	TTOO	T2 Biosystems	-94.8%	-99.0%
4	NXTT	Next Technology	-86.5%	-89.4%
5	OTRK	Ontrak	-78.2%	-96.6%
6	SCGY	Scientific Energy	-72.7%	-26.9%
7	PPCB	Propanc Biopharma	-72.1%	-79.1%
8	MGAWF	Megaworld	-71.0%	-71.0%
9	PTTMF	PT Timah	-62.8%	-83.1%
10	PIGEF	Pigeon	-62.4%	-62.4%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	XELA	Exela Technologies	212.4%	-95.5%
2	TKCM	Token Communities	82.8%	-64.7%
3	ANGGF	Angang Steel	61.2%	25.0%
4	BATMF	British American Tobacco Malaysia	43.4%	59.2%
5	KYSEF	Kyushu Electric Power	32.1%	32.1%
6	STTK	Shattuck Labs	26.7%	5.8%
7	KTHAF	Krung Thai Bank	24.0%	24.0%
8	SFOSF	Shanghai Fosun Pharmaceutical	23.7%	61.7%
9	INDOY	Indorama Ventures	20.9%	-5.5%
10	M	Macy's	20.7%	-1.0%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
2	MGAWF	Megaworld	-71.0%	-71.0%
3	PTTMF	PT Timah	-62.8%	-83.1%
4	PTJSF	PT Jasa Marga	-50.9%	-50.9%
5	UNLRF	PT Unilever Indonesia	-41.3%	-17.6%
6	DLNDY	D&L Industries	-37.5%	-30.7%
7	SUCEF	Sumitomo Osaka Cement	-37.4%	-37.4%
8	PTKFF	PT Kalbe Farma	-34.7%	-32.1%
9	SMTGF	SMA Solar Technology	-30.1%	28.4%
10	PMDKF	PT Mitra Adiperkasa	-28.6%	-48.9%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	EAF	GrafTech International	804.0%	-47.2%
2	RLMD	Relmada Therapeutics	122.3%	182.7%
3	XELA	Exela Technologies	109.6%	-95.5%
4	PSNYW	Polestar Automotive UK	96.2%	141.5%
5	TKCM	Token Communities	82.8%	-64.7%
6	PHJMF	PT Hanjaya Mandala Sampoerna	66.7%	34.8%
7	ANGGF	Angang Steel	61.2%	25.0%
8	DTNOF	DNO	49.5%	141.9%
9	BW	Babcock & Wilcox Enterprises	48.5%	54.9%
10	MDB	MongoDB	46.0%	34.4%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	COSG	Grand Gallery	-100.0%	�
2	PTLKF	PT Lippo Karawaci	-95.2%	-94.7%
3	NXTT	Next Technology	-74.5%	-89.4%
4	SCGY	Scientific Energy	-72.7%	-26.9%
5	MGAWF	Megaworld	-71.0%	-71.0%
6	TTOO	T2 Biosystems	-67.7%	-99.0%
7	PTTMF	PT Timah	-62.8%	-83.1%
8	PIGEF	Pigeon	-62.4%	-62.4%
9	NEGG	Newegg Commerce	-53.8%	290.6%
10	PTJSF	PT Jasa Marga	-50.9%	-50.9%

Peer Comparisons for Ascendis Pharma

Financials

	ASND	VRTX	ABBV	AMGN	GILD	REGN	Median
Name	Ascendis.	Vertex P.	AbbVie	Amgen	Gilead S.	Regenero.
Mkt Price	-	401.00	211.92	286.92	112.71	577.90	286.92
Mkt Cap	-	102.9	374.7	154.4	140.3	60.7	140.3
Rev LTM	-	11,419	58,328	34,917	28,862	14,214	28,862
Op Inc LTM	-	-199	13,695	8,192	10,797	3,841	8,192
FCF LTM	-	3,500	18,239	10,605	9,369	3,556	9,369
FCF 3Y Avg	-	1,984	20,273	8,590	8,397	3,248	8,397
CFO LTM	-	3,846	19,283	12,013	9,868	4,744	9,868
CFO 3Y Avg	-	2,324	21,154	9,753	8,949	4,518	8,949

Growth & Margins

	ASND	VRTX	ABBV	AMGN	GILD	REGN	Median
Name	Ascendis.	Vertex P.	AbbVie	Amgen	Gilead S.	Regenero.
Rev Chg LTM	-	10.5%	6.1%	12.9%	3.8%	5.4%	6.1%
Rev Chg 3Y Avg	-	11.0%	0.6%	10.0%	1.6%	0.3%	1.6%
Rev Chg Q	-	12.1%	6.6%	9.4%	1.8%	3.6%	6.6%
QoQ Delta Rev Chg LTM	-	2.9%	1.7%	2.3%	0.4%	0.9%	1.7%
Op Mgn LTM	-	-1.7%	23.5%	23.5%	37.4%	27.0%	23.5%
Op Mgn 3Y Avg	-	26.5%	27.2%	26.4%	39.2%	30.1%	27.2%
QoQ Delta Op Mgn LTM	-	2.0%	1.0%	1.6%	-0.0%	-0.2%	1.0%
CFO/Rev LTM	-	33.7%	33.1%	34.4%	34.2%	33.4%	33.7%
CFO/Rev 3Y Avg	-	22.5%	37.5%	32.0%	31.9%	33.6%	32.0%
FCF/Rev LTM	-	30.6%	31.3%	30.4%	32.5%	25.0%	30.6%
FCF/Rev 3Y Avg	-	19.2%	36.0%	28.2%	30.0%	24.1%	28.2%

Valuation

	ASND	VRTX	ABBV	AMGN	GILD	REGN	Median
Name	Ascendis.	Vertex P.	AbbVie	Amgen	Gilead S.	Regenero.
Mkt Cap	-	102.9	374.7	154.4	140.3	60.7	140.3
P/S	-	9.0	6.4	4.4	4.9	4.3	4.9
P/EBIT	-	23.4	63.6	14.9	17.1	12.4	17.1
P/E	-	28.3	99.6	23.3	22.2	13.6	23.3
P/CFO	-	26.8	19.4	12.8	14.2	12.8	14.2
Total Yield	-	3.5%	4.0%	7.5%	7.3%	7.6%	7.3%
Dividend Yield	-	0.0%	3.0%	3.2%	2.8%	0.3%	2.8%
FCF Yield 3Y Avg	-	2.1%	7.3%	6.2%	8.0%	4.4%	6.2%
D/E	-	0.0	0.2	0.4	0.2	0.0	0.2
Net D/E	-	-0.0	0.2	0.3	0.1	-0.1	0.1

Returns

	ASND	VRTX	ABBV	AMGN	GILD	REGN	Median
Name	Ascendis.	Vertex P.	AbbVie	Amgen	Gilead S.	Regenero.
1M Rtn	-	-13.2%	8.6%	-2.6%	-0.4%	3.6%	-0.4%
3M Rtn	-	-10.2%	14.2%	-0.1%	3.8%	18.6%	3.8%
6M Rtn	-	-17.5%	3.8%	-6.5%	-0.4%	-14.2%	-6.5%
12M Rtn	-	-19.1%	11.8%	-11.2%	47.3%	-51.0%	-11.2%
3Y Rtn	-	42.7%	74.1%	30.3%	97.4%	-0.0%	42.7%
1M Excs Rtn	-	-16.1%	5.7%	-5.4%	-3.3%	0.7%	-3.3%
3M Excs Rtn	-	-18.1%	6.2%	-7.8%	-3.9%	9.8%	-3.9%
6M Excs Rtn	-	-26.7%	-7.7%	-15.8%	-11.1%	-25.0%	-15.8%
12M Excs Rtn	-	-32.8%	-2.4%	-24.7%	33.4%	-66.3%	-24.7%
3Y Excs Rtn	-	-15.1%	17.5%	-24.3%	45.4%	-56.7%	-15.1%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End		12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date		2/12/2025	2/7/2024	2/16/2023	3/2/2022	3/10/2021	4/3/2020
Key Financials
Total Revenue	426	364	267	51	8	7	13
Ebitda	-189	-290	-411	-529	-365	-408	-210
Operating Income	-283	-279	-456	-562	-452	-331	-227
Net Income	-286	-378	-481	-583	-384	-419	-218
EPS	-4.91	-6.53	-8.55	-10.40	-7.00	-8.28	-4.69
Growth Rates
Total Revenue Growth	29.4%	36.3%	421.2%	557.9%	11.9%	-48.0%	26.4%
EBITDA Growth	46.7%	29.5%	22.3%	-45.1%	10.6%	-93.9%	-62.4%
Operating Income Growth	21.7%	38.8%	18.9%	-24.4%	-36.6%	-45.8%	-46.5%
Net Income Growth	43.0%	21.5%	17.4%	-52.0%	8.4%	-92.2%	-67.6%
Margins
EBITDA Margin	-44.4%	-79.8%	-154.2%	-1034.1%	-4688.1%	-5865.2%	-1572.6%
Operating Income Margin	-66.4%	-76.7%	-170.8%	-1097.9%	-5808.6%	-4755.1%	-1695.1%
Net Income Margin	-67.1%	-104.0%	-180.5%	-1139.6%	-4931.6%	-6025.5%	-1630.0%
Cash & Debt
Total Cash	�	560	399	735	682	719	598
Total Debt	0	857	644	508	105	92	37
Net Debt / (Cash)	�	297	245	-227	-577	-627	-561
Cash Flows
Net Cash from Operations	-212	-306	-467	-496	-418	-272	-176
Free Cash from Operations	-218	-308	-470	-510	-442	-293	-181
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	105	22	-0	-0

$ Mil \| FY: 12/31	2025Q2	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2
Period End	6/30/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022	6/30/2022
Filing Date	8/7/2025	2/12/2025	11/14/2024	9/3/2024	5/2/2024	2/7/2024	11/7/2023	9/5/2023	4/27/2023	2/16/2023	11/2/2022	8/10/2022
Key Financials Quarterly
Total Revenue	158	174	58	36	96	138	48	47	34	23	15	6
Ebitda	2	-38	-68	-85	-47	-68	-132	-108	-95	-192	-123	-68
Operating Income	-53	0	-97	-133	-49	-37	-134	-141	-144	-147	-145	-142
Net Income	-39	-38	-99	-109	-131	-87	-162	-121	-111	-207	-169	-81
EPS	-0.64	-0.64	-1.72	-1.91	-2.30	-1.54	-2.88	-2.16	-1.98	-3.70	-3.03	-1.46
Key Financials TTM
Total Revenue TTM	426	364	327	318	329	267	152	119	78	51	33	19
Ebitda TTM	-189	-238	-268	-332	-355	-403	-528	-519	-478	-498	-407	-359
Operating Income TTM	-283	-279	-316	-353	-361	-456	-566	-576	-577	-562	-527	-479
Net Income TTM	-286	-378	-426	-490	-502	-481	-602	-609	-569	-583	-482	-393
Growth Rates Quarterly
Total Revenue Growth	64.8%	26.3%	20.4%	-24.0%	185.5%	501.4%	214.2%	669.4%	391.9%	367.6%	1273.8%	502.7%
EBITDA Growth	104.9%	44.0%	48.3%	21.1%	50.8%	64.8%	-7.3%	-59.7%	17.5%	-91.0%	-63.0%	43.1%
Operating Income Growth	-7.7%	101.0%	28.0%	5.4%	65.8%	75.2%	7.0%	0.7%	-12.2%	-30.9%	-49.1%	-20.6%
Net Income Growth	70.3%	55.7%	38.9%	9.9%	-18.1%	58.1%	4.0%	-49.3%	11.6%	-95.6%	-110.3%	39.5%
Margins Quarterly
EBITDA Margin	1.5%	-21.8%	-118.4%	-236.5%	-48.9%	-49.2%	-275.5%	-227.6%	-283.5%	-839.1%	-806.8%	-1096.4%
Operating Income Margin	-33.5%	0.2%	-167.3%	-370.2%	-51.2%	-26.6%	-279.8%	-297.2%	-427.8%	-643.7%	-945.1%	-2303.5%
Net Income Margin	-24.6%	-22.1%	-171.5%	-303.9%	-136.6%	-63.1%	-337.7%	-256.2%	-330.2%	-905.9%	-1105.0%	-1320.1%
Cash & Debt
Total Cash	-	560	626	259	320	399	455	431	586	735	920	955
Total Debt	0	857	789	673	669	644	666	506	505	508	553	512
Net Debt / (Cash)	-	297	163	414	349	245	210	75	-80	-227	-367	-443
Cash Flows Quarterly
FCF from Operations	-7	-87	-56	-61	-102	-42	-125	-153	-147	-142	-99	-124
Cash Flows TTM
FCF from Operations TTM	-212	-306	-261	-330	-422	-467	-567	-541	-512	-496	-477	-476
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	0	-0	0
Return on Invested Capital (ROIC) Quarterly
ROIC	-	0.5%	-14.8%	-128.8%	-56.4%	-59.8%	-255.5%	-401.9%	-661.8%	-1625.4%	-679.5%	-34.2%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-	-93.8%	-12.1%	-85.4%	-103.5%	-186.1%	-269.1%	-412.7%	-665.0%	-1549.0%	-620.0%	-28.9%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
SKYTROFA®	179	36
Collaboration partners and license agreements	88	16
YORVIPATH®	0	0
Licenses			2	3	1
Rendering of services			1	2	10
Sale of clinical supply			4	2	3
Sale of commercial products			1
Total	267	51	8	7	13

Price Behavior

Behavior Stats
Betas Matrix

Price Behavior

Market Price	$200.02
Market Cap ($ Bil)	12.1
First Trading Date	02/15/2008
Distance from 52W High	0.0%
	50 Days	200 Days
DMA Price	$181.21	$155.92
DMA Trend	up	up
Distance from DMA	10.4%	28.3%
	3M	1YR
Volatility	33.8%	46.5%
Downside Capture	-39.05	81.38
Upside Capture	53.82	107.40
Correlation (SPY)	12.8%	20.7%
	5D	10D
Expected Return	2.0%	8.3%
Expected Excess Return	-2.0%	4.9%
Chance of Rise	47.1%	62.5%
Std Dev of Returns	1.7%	4.4%

ASND Betas & Captures as of 8/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	0.46	0.74	0.65	0.36	0.49	0.64
Up Beta	2.14	2.12	2.00	0.10	0.10	0.64
Down Beta	0.49	-1.08	-0.76	0.34	0.38	0.69
Up Capture	62%	104%	85%	80%	112%	37%
Bmk +ve Days	10	22	35	71	142	415
Stock +ve Days	15	24	31	64	121	370
Down Capture	-148%	-11%	-14%	63%	91%	80%
Bmk -ve Days	11	19	27	54	106	334
Stock -ve Days	6	17	31	61	127	379

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	8152025
Short Interest: Shares Quantity	2,487,423
Short Interest: % Change Since 7312025	-9.7%
Average Daily Volume	622,417
Days-to-Cover Short Interest	4
Basic Shares Quantity	60,454,589
Short % of Basic Shares	4.1%

SEC Filings

Expand for More

Report Date	Filing
6302025	6-K 6/30/2025
12312024	20-F 12/31/2024
9302024	6-K 9/30/2024
6302024	6-K 6/30/2024
3312024	6-K 3/31/2024
12312023	20-F 12/31/2023
9302023	6-K 9/30/2023
6302023	6-K 6/30/2023
3312023	6-K 3/31/2023
12312022	20-F 12/31/2022
9302022	6-K 9/30/2022
6302022	6-K 6/30/2022
3312022	6-K 3/31/2022
12312021	20-F 12/31/2021
9302021	6-K 9/30/2021
6302021	6-K 6/30/2021

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
ASND Return	20%	-19%	-9%	3%	9%	45%	-8%
Peers Return	11%	18%	23%	15%	2%	8%	103%
S&P 500 Return	16%	27%	-19%	24%	23%	10%	100%
Monthly Win Rates [3]
ASND Win Rate	58%	33%	50%	58%	67%
Peers Win Rate	55%	55%	55%	53%	57%	63%
S&P 500 Win Rate	58%	75%	42%	67%	75%	57%
Max Drawdowns [4]
ASND Max Drawdown	-30%	-32%	-42%	-43%	-10%	-9%
Peers Max Drawdown	-16%	-9%	-7%	-11%	-11%	-10%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

Ascendis Pharma (ASND)

Market Price (9/4/2025): $200.1 | Market Cap: $12.1 BilSector: Health Care | Industry: Biotechnology

Ascendis Pharma (ASND)

Market Price (9/4/2025): $200.1Market Cap: $12.1 BilSector: Health CareIndustry: Biotechnology

Investment Highlights

Market Valuation

Stock Price Chart

Market Cap Chart

Business Description

Price Returns Compared

Interactive Breakdown

Better Bets than Ascendis Pharma (ASND)

Latest Trefis Analyses

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Ascendis Pharma

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (9/4/2025): $200.1 | Market Cap: $12.1 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (9/4/2025): $200.1
Market Cap: $12.1 Bil
Sector: Health Care
Industry: Biotechnology